Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth

Peyman Ghorbani¹,²,³, Prisila Santhakumar¹, Qingda Hu¹,², Pascal Djiaude¹, Thomas M.S. Wolever⁴, Nades Palaniyar¹,²,⁵ and Hartmut Grasemann¹,⁵,⁶

Affiliations: ¹Program in Physiology and Experimental Medicine, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada. ²Dept of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. ³Institute for Infection Immunology, TWINCORE, Hannover, Germany. ⁴Dept of Nutritional Sciences, University of Toronto, Toronto, ON, Canada. ⁵Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada. ⁶Dept of Pediatrics, Division of Respiratory Medicine, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada.

Correspondence: Hartmut Grasemann, The Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada. E-mail: Hartmut.Grasemann@sickkids.ca

ABSTRACT The hypoxic environment of cystic fibrosis airways allows the persistence of facultative anaerobic bacteria, which can produce short-chain fatty acids (SCFAs) through fermentation. However, the relevance of SCFAs in cystic fibrosis lung disease is unknown. We show that SCFAs are present in sputum samples from cystic fibrosis patients in millimolar concentrations (mean±SEM 1.99±0.36 mM).

SCFAs positively correlated with sputum neutrophil count and higher SCFAs were predictive for impaired nitric oxide production. We studied the effects of the SCFAs acetate, propionate and butyrate on airway inflammatory responses using epithelial cell lines and primary cell cultures. SCFAs in concentrations present in cystic fibrosis airways (0.5–2.5 mM) affected the release of granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor and interleukin (IL)-6. SCFAs also resulted in higher IL-8 release from stimulated cystic fibrosis transmembrane conductance regulator (CFTR) F508del-mutant compared to wild-type CFTR-corrected bronchial epithelial cells. At 25 mM propionate reduced IL-8 release in control but not primary cystic fibrosis epithelial cells. Low (0.5–2.5 mM) SCFA concentrations increased, while high (25–50 mM) concentrations decreased inducible nitric oxide synthase expression. In addition, SCFAs affected the growth of Pseudomonas aeruginosa in a concentration- and pH-dependent manner.

Thus, our data suggest that SCFAs contribute to cystic fibrosis-specific alterations of responses to airway infection and inflammation.

@ERSpublications

Short-chain fatty acids contribute to CF-specific alterations of responses to airway infection and inflammation http://ow.ly/L7ZI9
Introduction
Cystic fibrosis lung disease is characterised by chronic inflammation as well as recurrent and persistent infections of the airways with certain pathogens [1]. Mucus accumulation contributes to inflammation and infection, as well as to sustaining a hypoxic environment [2]. Many typical cystic fibrosis pathogens, including *Staphylococcus aureus*, *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Pseudomonas aeruginosa*, are facultative anaerobes [3]. Recent advances in metagenomic analysis of the lung microbiome have further revealed a major presence of obligate anaerobic species in cystic fibrosis airways [4, 5], but the clinical relevance of these species in cystic fibrosis lung disease is still unclear.

Metabolism in anaerobic bacteria proceeds in the absence of oxygen. Fermentation of carbohydrates and amino acids results in the formation of short-chain fatty acids (SCFAs) such as acetate (CH₃COO⁻), propionate (C₂H₅COO⁻) and butyrate (C₃H₇COO⁻) in descending order of abundance. In the large intestine, SCFAs can be found at concentrations ranging from 30 to 150 mM [6]. These metabolites regulate a multitude of functions including intestinal epithelial homeostasis, energy provision, inflammation, regulatory T-cell development and microbial diversity [7, 8].

We hypothesised that SCFAs play a role in cystic fibrosis lung disease, specifically in inflammatory responses and host defence against *Pseudomonas* infection. Our gas chromatography measurements detected millimolar concentrations of SCFAs in sputum obtained from patients with cystic fibrosis. We therefore assessed the effect of SCFAs on inflammation in an alveolar epithelial cell line (A549), cystic fibrosis bronchial epithelial cell lines and primary cell cultures from cystic fibrosis and control donors. We also examined the effect of SCFAs on the growth of *P. aeruginosa* strains. We found that SCFAs at concentrations measured in cystic fibrosis sputum affect the inflammatory responses of airway epithelial cells and the growth of *P. aeruginosa*.

Methods

**Sputum samples**
Sputum samples were obtained from patients with cystic fibrosis as previously described [9] at the Hospital for Sick Children (Toronto, ON, Canada) in accordance with research ethics board approval (The Hospital for Sick Children; 1000019444) [10]. Samples were obtained from clinically stable patients, as well as from patients with a pulmonary exacerbation prior to and following 2 weeks of intravenous antibiotic treatment. See table 1 for patient characteristics.

Solid mucus plugs from sputum samples were processed by treatment with 0.1% Sputolysin (dithiothreitol, Calbiochem, Etobicoke, ON, Canada) in water [9]. The homogenised sputum was then centrifuged and the supernatant frozen at −80°C for future analysis.

**SCFA gas chromatography**
Sputum supernatants were filtered through 30 kDa ultrafiltration devices (Sartorius or Millipore Vivaspin; Sartorius, Mississauga, ON, Canada or Amicon Ultra; Millipore, Etobicoke, ON, Canada). The filtered supernatants were then acidified using formic acid and spiked with an internal standard, 2-methylbutyric acid. Volatile compounds from the acidified filtrates were then distilled under reduced pressure and liquid nitrogen temperatures, dissolved in ultrapure water and injected into a gas chromatography apparatus with flame ionisation detector. Sample SCFA concentrations were calculated based on a standard curve of SCFAs analysed in the same fashion.

**TABLE 1 Patient characteristics**

<table>
<thead>
<tr>
<th></th>
<th>Stable</th>
<th>Pulmonary exacerbation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Before antibiotic treatment</td>
<td>After antibiotic treatment</td>
</tr>
<tr>
<td>Subjects</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Age years</td>
<td>13.5±2.0</td>
<td>13.3±3.4</td>
</tr>
<tr>
<td>Sex M/F</td>
<td>6/5</td>
<td>5/4</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>87.3±18.0</td>
<td>52.9±11.9</td>
</tr>
<tr>
<td></td>
<td>63.2±14.3</td>
<td></td>
</tr>
<tr>
<td>Predominant bacterial species (n)</td>
<td><em>P. aeruginosa</em> [2], <em>S. aureus</em> [3]</td>
<td><em>P. aeruginosa</em> [3], <em>P. aeruginosa</em> [1], <em>S. aureus</em> [3]</td>
</tr>
</tbody>
</table>

Data are presented as n or mean±SEM. FEV1: forced expiratory volume in 1 s; *P. aeruginosa*: *Pseudomonas aeruginosa*; *S. aureus*: *Staphylococcus aureus*. 2 DOI: 10.1183/09031936.00143614
**Bacterial culture and strains**

Bacteria were cultured either from glycerol stocks kept at −80°C or from single colonies selected from trypticase soy agar plates. *P. aeruginosa* strains PAO1 and PA508 (a gift from the laboratory of Neil B. Sweezey, The Hospital for Sick Children) were cultured in trypticase soy broth (TSB) at 37°C for all experiments. Bacteria were grown overnight in TSB at 37°C and 225 rpm shaking, and further diluted in TSB modified with different concentrations of SCFAs or other chemicals (sodium acetate, sodium propionate, sodium butyrate and sodium l-lactate) and adjusted to pH 7.0, 6.5, 6.0 and 5.5 with hydrochloric acid. Microplates were read on an Omega plate reader (BMG Labtech, Cary, NC, USA) for optical density at 600 nm. For analysis, blank TSB-corrected optical density readings were normalised to pH-matched TSB controls for each time point. For microaerobic conditions, plates were sealed using optically clear PCR film at the start of the experiment. Due to condensation on the film, optical density was read at 600 nm and subtracted by optical density at 800 nm.

**Cell lines and culture**

A549 human adenocarcinomic alveolar basal epithelial cells, cystic fibrosis bronchial epithelial 41o-immortalised cells from a patient with homozygous F508del cystic fibrosis transmembrane conductance regulator (CFTR) alleles transfected with F508del (CFBE) or wild-type CFTR vector (corrCFBE) were used in this work. A549 and CFBE cells were cultured in 10% v/v fetal bovine serum in DMEM (Wisent Bioproducts, St Bruno, QU, Canada) with 4.5 g·L⁻¹ glucose, 110 mg·L⁻¹ sodium pyruvate, 2 mM L-glutamine, 100 units·mL⁻¹ penicillin/streptomycin at 37°C and 5% CO₂. CFBE and corrCFBE cells were cultured with 300 µg·mL⁻¹ hygromycin B.

Primary human bronchial epithelial cells were obtained from control or cystic fibrosis donors from the Primary Airway Cell Biobank (McGill University, Montreal, QU, Canada) and cultured in bronchial epithelial growth medium. Human bronchial epithelial cells were cultured in bronchial epithelial growth medium containing 10% bovine serum albumin, 50 µg·mL⁻¹ gentamycin, 100 units·mL⁻¹ penicillin, 100 µg·mL⁻¹ streptomycin and 250 µg·mL⁻¹ amphotericin B. Cells were passaged once before reaching 80–90% confluence and thereafter cultured until 90% confluence and subsequently used for the experimental procedure.

**Cytomix stimulation**

A549, CFBE, corrCFBE or primary human bronchial epithelial cells were seeded in 12- or 24-well plates and grown to 70–90% confluence. Plates were then washed, replenished with serum-free media and incubated for 24 h. Cells were then incubated for 1 h with various SCFAs prior to cytomix (10 ng·mL⁻¹ each of interleukin (IL)-1β, tumour necrosis factor (TNF)-α and interferon (IFN)-γ) stimulation and further incubation for specified times. SCFA concentrations were chosen based on ranges found in the colonic lumen (10–50 mM) and in cystic fibrosis airways (0.1–5 mM), and from previous studies.

**Western blot**

Samples were electrophoresed and transferred onto nitrocellulose membranes. Membranes were incubated with anti-inducible nitric oxide synthase (iNOS) or anti-glyceraldehyde 3-phosphate dehydrogenase antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) and anti-rabbit horseradish peroxidase conjugated secondary antibodies (Santa Cruz). Enhanced chemiluminescent substrate (Thermo, Mississauga, ON, Canada) was added directly onto each membrane and developed using radiographic film on a Kodak X-Omat 2000a processor (Windsor, CO, USA).

**Cytokine analysis**

Cell culture supernatants were analysed for cytokines using a Milliplex kit (Millipore) according to the manufacturer’s protocol. IL-8 concentrations were measured using a commercial ELISA kit (PeproTech, Rocky Hill, NJ, USA).

**Proliferation/viability assays**

For proliferation assays, cells were seeded at 5×10⁴ cells·mL⁻¹ in 96-well plates and incubated for 1 h with SCFAs, then incubated for 24 h with PrestoBlue reagent according to the manufacturer’s protocol (Molecular Probes, Burlington, ON, Canada). To assess viability, cells were grown to 80–90% confluence in 96-well plates before incubation with SCFAs.

**Statistical procedures**

Statistical analysis was performed using Microsoft Excel (Redmond, WA, USA) or GraphPad Prism 5 (La Jolla, CA, USA). For sputum SCFAs, unpaired and paired nonparametric t-tests were performed, as well as linear regressions for correlation analyses. For bacterial growth data, repeated measures ANOVA were performed followed by Dunnett’s post-test to compare growth curves against the buffer control. For all
Results

SCFAs in sputum of patients with cystic fibrosis

SCFAs were found in cystic fibrosis patient sputum in millimolar concentrations (fig. 1a). In clinically stable subjects, mean (range) total SCFA concentration was 1991 µM (821–4064 µM). For patients presenting with a cystic fibrosis pulmonary exacerbation, mean (range) total SCFA concentrations before antibiotic treatment and after 2 weeks treatment with i.v. antibiotics were 1280 µM (158–4570 µM) and 873 µM (166–4178 µM), respectively (fig. 1a). Mean total SCFA concentrations were significantly lower after treatment when compared to stable patients (p=0.0076 using Mann–Whitney U-test). Although SCFA concentrations decreased for the majority (seven out of nine) of patients after antibiotic treatment, this decrease was statistically nonsignificant (fig. 1a) (n=9, p=0.2031 using Wilcoxon paired test).

The number of neutrophils in sputum is an established marker of cystic fibrosis airways inflammation. Sputum neutrophil counts showed a significant positive correlation with total SCFAs in stable patients (fig. 1b) (n=10, r²=0.8743, p<0.0001), but not in patients with pulmonary exacerbation, either before (n=9, r²=0.0055, p=0.85) or after antibiotic treatment (n=9, r²=0.1999, p=0.2276).

Airway nitric oxide (NO) has previously been shown to be decreased in cystic fibrosis and both exhaled NO and sputum oxides of nitrogen (NOx) increase after antibiotic treatment for cystic fibrosis pulmonary exacerbations [11, 12]. Total SCFAs in patients before treatment with antibiotics correlated negatively with the fold change in sputum NOx following antibiotic treatment (fig. 1c) (n=7, r²=0.7493, p<0.05), suggesting that high SCFA concentrations in sputum prior to treatment with antibiotics prevented the expected increase in airway NO production. However, there was no correlation between SCFAs and fold change in sputum IL-8 concentrations following antibiotic treatment (fig. 1d) (n=9, r²=0.0004, p=0.9605).

SCFAs modulate inflammatory responses of airway epithelial cells

SCFAs have been shown to exert pro- or anti-inflammatory effects on intestinal epithelial cells, depending on their concentration [13–16]. To investigate the effects of SCFAs on inflammatory responses of airway and alveolar epithelial cells, we stimulated cells with a mix of IL-1β, IFN-γ and TNF-α after SCFA pretreatment. Predominant cytokines secreted by A549 alveolar basal epithelial cells were granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1α, IL-6 (fig. 2a-c) and IL-8 (data not shown). Pre-incubation with SCFAs upregulated the production of GM-CSF and IL-1α, and less so IL-6, in a concentration-dependent manner. Interestingly, while all SCFAs at 0.5–5 mM upregulated GM-CSF and IL-1α production, acetate at 25 mM resulted in upregulated GM-CSF, IL-1α and IL-6 (fig. 2a–c).

Cystic fibrosis airways exhibit a persistent inflammatory environment and several cytokines including GM-CSF, IL-1, IL-6, IL-8, IFN-γ and TNF-α are present in cystic fibrosis airways in high concentrations [17, 18]. Therefore, we next examined the impact of SCFAs on the inflammatory profile of CFBE cells [19], the most common cystic fibrosis-causing mutation in Caucasians [1], transfected with a vector overexpressing F508del-CFTR. As a control we used the same cell line transfected with a vector overexpressing wild-type
CFTR (corrCFBE) [20]. Similar to the results in A549 cells, SCFAs at 0.5–2.5 mM, in particular propionate, increased GM-CSF, and granulocyte (G)-CSF production in cytokine-stimulated corrCFBE cells, but not in CFBE cells (fig. 3a and c), while propionate upregulated IL-6 in both cell lines (fig. 3b). Acetate at 0.5 mM reduced IL-6 expression in CFBE but not corrCFBE cells. A mix of acetate (0.5 mM), propionate (0.1 mM) and butyrate (0.005 mM) also resulted in increased IL-6 and G-CSF in the corrCFBE cells only (fig. 3b and c, APB low). In contrast, the production of IL-8, a key cytokine for granulocyte recruitment found in high concentrations in cystic fibrosis airways, was upregulated in the presence of 0.5–2.5 mM acetate in stimulated CFBE but not in corrCFBE cells (fig. 3d).

In primary airway epithelial cells, we found that high (25 mM) propionate concentrations downregulated GM-CSF, IL-6 and G-CSF in both cystic fibrosis and non-cystic fibrosis control cells with or without cytokinin stimulation (fig. 4a–f). In contrast, low (0.5 mM) propionate concentrations upregulated G-CSF in stimulated cystic fibrosis but not control cells (fig. 4f), in contrast to the findings in the CFBE cells. We also observed that 25 mM propionate reduced IL-8 in primary control but not cystic fibrosis cells, in the absence of cytokinin stimulation (fig. 4g). SCFAs did not affect IL-8 production with cytokinin stimulation in either control or cystic fibrosis cells, possibly due to the high basal IL-8 levels following cytokinin stimulation (fig. 4h).

Next we examined epithelial cells for iNOS expression under inflammatory cytokinin stimulation. Interestingly, low concentrations (0.5–2.5 mM) of SCFAs increased iNOS expression in A549 cells above cytokinin stimulation alone at early (4 h and 8 h) (online supplementary figs S1a and b and S2a and b) and late (24 h) time points (fig. 5a–c and figs S1c and S2c). In contrast, at higher concentrations (25–50 mM), similar to those previously reported in the intestines of healthy subjects, individual SCFAs or SCFAs in combination significantly reduced cytokinin-induced iNOS expression (fig. 5 and figs S1 and S2). The expression of iNOS was absent in unstimulated A549 cells and was not upregulated by butyrate (fig. 5) or acetate/propionate alone (data not shown). We were unable to detect iNOS in the transfected cystic fibrosis
FIGURE 3 Short-chain fatty acids (SCFAs) modulate cytokine secretion in cystic fibrosis bronchial epithelial cells. Bronchial epithelial 41o-immortalised cells from a patient with homozygous F508del cystic fibrosis transmembrane conductance regulator (CFTR) alleles transfected with F508del (CFBE41o-/F508del) or wild-type CFTR vector (CFBE41o-/corrCFTR) cell lines in response to SCFA incubation and stimulation with cytomix (10 ng·mL\(^{-1}\) each of interleukin (IL)-1β, tumour necrosis factor-α and interferon-γ) for 24 h. Secretion of a) granulocyte-macrophage colony-stimulating factor (GM-CSF); b) IL-6; c) granulocyte-colony-stimulating factor; and d) IL-8 are shown relative to cytokine stimulation alone (cytomix). Data are presented as mean±SEM. Ace: acetate; Prp: propionate; But: butyrate; APB high: 2.5 mM acetate, 0.5 mM propionate and 0.05 mM butyrate; APB low: 0.5 mm acetate, 0.1 mM propionate and 0.005 mM butyrate. *: p<0.05; **: p<0.01; ***: p<0.001; ¶: p=0.08 (nonparametric unpaired t-tests).
cell lines (CFBE or corrCFBE) before or after cytokine stimulation, in line with previous reports [21]. In primary cultures of non-cystic fibrosis airway epithelial cells, expression of iNOS in response to SCFA incubation and cytokine stimulation was similar to A549 cells (fig. 6). In stimulated primary cystic fibrosis epithelial cells, iNOS protein expression was detectable but was reduced in comparison with control cells. Importantly, and in line with the findings in A549 and non-cystic fibrosis control cells, expression of iNOS in cystic fibrosis primary cells was further reduced to undetectable levels with high (25 mM) propionate treatment, but low (0.5 mM) propionate resulted in increased iNOS expression (fig. 6).

Thus, our data suggest that SCFAs mediate important changes in epithelial cell inflammatory cytokine production and iNOS expression, and that cystic fibrosis epithelial cells respond differently to SCFA exposure than do non-cystic fibrosis cells.

**SCFAs alter growth of* P. aeruginosa***

*Pseudomonas aeruginosa* is a facultative anaerobe, and can produce SCFAs [22]. Since the presence of SCFAs may influence bacterial metabolism, we asked whether SCFAs affect the growth of *P. aeruginosa*. In these *in vitro* experiments we observed a dichotomous concentration-dependent effect of SCFAs on bacterial growth. At high concentrations, propionate (fig. 7), acetate and butyrate (online supplementary figs S3 and S4) inhibited *P. aeruginosa* growth over ≥6 h. In contrast, we saw that low concentrations of SCFAs resulted in enhanced bacterial growth, particularly during the mid-log phase of growth. Cystic fibrosis airway secretions have been shown to have a slightly acidic pH [23], although this observation is controversial [24]. As SCFAs have a higher proportion of protonated species in acidic conditions, their diffusion through membranes is greatly enhanced [7]. Therefore we also tested bacterial growth conditions
at different pH. We found that at decreased pH there was uniformly lower bacterial growth with SCFA incubation (fig. 7). We used the laboratory *P. aeruginosa* strain PAO1 for these experiments, and observed comparable results with a clinical isolate PA508 (online supplementary fig. S5 and data not shown).

<table>
<thead>
<tr>
<th>Butyrate mM</th>
<th>0.5</th>
<th>2.5</th>
<th>25</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 h stimulation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8 h stimulation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>24 h stimulation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**FIGURE 5** Short-chain fatty acids (SCFAs) modulate inducible nitric oxide synthase (iNOS) expression in A549 cells. iNOS and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in A549 cells pre-incubated for 1 h with different concentrations of butyrate (0.5 mM, 2.5 mM, 25 mM and 50 mM) and stimulated with or without cytomix ((CM) 10 ng·mL\(^{-1}\) each of interferon-γ, tumour necrosis factor-α and interleukin-1β) for a) 4 h, b) 8 h and c) 24 h. Data are presented as representative Western blots or d) quantification of at least two independent experiments performed in duplicate. Samples and controls for each time point were run on the same gel. Fold change relative to cytokine stimulation alone (CM) is displayed.
As the environment of cystic fibrosis sputum is hypoxic, we sought to determine the effect of SCFAs on *P. aeruginosa* growth under such conditions. We observed that SCFAs caused significant growth inhibition, which was amplified at lower pH, and that overall growth was considerably reduced compared to aerobic conditions (online supplementary fig. S6). Collectively, we conclude that SCFAs alter the growth of *Pseudomonas* strains in a concentration- and pH-dependent manner.

**Discussion**

This is the first study to quantitatively assess the presence of SCFAs in the airway secretions of patients with cystic fibrosis. Sputum SCFA concentrations were found in the millimolar range in both clinically stable patients and those presenting with a pulmonary exacerbation. Antibiotic treatment resulted in a decrease in SCFA levels in most, but not all sputum samples, suggesting that bacteria contributed to the SCFA levels in sputum. However, as sputum SCFA levels before treatment for pulmonary exacerbation were not from clinically stable patients, other factors may also contribute to SCFAs in airways. These could include differences in quantitative and qualitative airway microbiology, bacterial metabolic activity, degree of airway inflammation, as well as differences in individual treatments. We then studied the effects of SCFAs on inflammatory responses of cultured airway epithelial cells. While high concentrations of propionate and butyrate reduced proliferation of A549 cells, they did not influence their viability (online supplementary fig. S7). Our findings show that SCFAs can influence the inflammatory response of airway epithelium and may contribute to differences between normal and cystic fibrosis airway inflammation, as well as differences in individual treatments. We then studied the effects of SCFAs on inflammatory responses of cultured airway epithelial cells. While high concentrations of propionate and butyrate reduced proliferation of A549 cells, they did not influence their viability (online supplementary fig. S7). Our findings show that SCFAs can influence the inflammatory response of airway epithelium and may contribute to differences between normal and cystic fibrosis airway inflammation. We found that high (25–50 mM) concentrations of SCFAs enhanced the induction of inflammatory cytokines such as GM-CSF and IL-6 in A549 and corrCFBE cells, whereas low (0.5–2.5 mM) concentrations of acetate upregulated IL-8 in CFBE but not corrCFBE cells. In primary cell cultures, high (25 mM) concentrations of SCFAs inhibited IL-8 production in non-cystic fibrosis controls, but not in cystic fibrosis airway epithelium, suggesting that SCFAs may contribute to increased IL-8 levels, which are characteristic of cystic fibrosis airway inflammation [17].

Interestingly, earlier studies investigating the effects of butyrate and its derivative 4-phenylbutyrate on pharmacological rescue of F508del-CFTR found, in line with our results, that 4-phenylbutyrate (at 6–10 mM) had a pro-inflammatory effect on CFBE cells (CFBE41o−, also used in this study, and IB3–1 cells) by
upregulating IL-8 [25, 26]. However, in our study there was no correlation between SCFA concentrations at the time of pulmonary exacerbation with IL-8 or the change in IL-8 after antibiotic treatment, and no correlation between the change in SCFA concentrations before and after antibiotic treatment with either the change in IL-8 or the levels of IL-8 after antibiotic treatment, illustrating that SCFAs may contribute to but are not the major factor affecting individual IL-8 levels. The SCFA-mediated changes in cytokine production from epithelial cell cultures suggest that SCFAs could lead to impaired resolution of inflammation and exacerbated persistence of neutrophils. This was supported by the significant positive correlation between SCFA concentrations and total neutrophil count in cystic fibrosis sputum. Apart from the effect on cytokine levels, SCFAs can induce chemotaxis in neutrophils, and may thus also have a direct effect on airway neutrophilia [27]. Larger studies are needed to further elucidate the link between SCFAs and airway inflammation in cystic fibrosis.

The expression of iNOS, an enzyme important for the production of protective reactive nitrogen species, is impaired in cystic fibrosis airway epithelium [21, 28, 29], and NO concentrations in the airways of patients with cystic fibrosis are typically decreased [30, 31]. However, antibiotic therapy for acute pulmonary exacerbations can lead to improved iNOS expression [32] and airway NO production [11, 12] in cystic fibrosis. Changes in NO metabolism following treatment of exacerbations correlated with improvement in pulmonary function [10, 33]; consequently, other more direct strategies to improve airway NO production in cystic fibrosis are being investigated [34, 35]. We show here that SCFAs can affect iNOS expression in a concentration-dependent manner in alveolar and airway epithelial cells in vitro. In A549 cells, normal control and primary cystic fibrosis epithelial cell cultures, low concentrations enhanced cytokine-stimulated iNOS expression. In contrast, high concentrations markedly abrogated iNOS expression in A549 as well as primary control and cystic fibrosis epithelial cells. While it is not clear whether the effect on iNOS expression was direct or mediated by changes in the inflammatory response, SCFAs and their derivatives have previously been shown to directly inhibit activation of nuclear factor-kB,
a key regulator of iNOS transcription [26, 36]. The presence of SCFAs in airways may contribute to the dysregulation of NOS in cystic fibrosis airways, which is supported by our observation that lower concentrations of these bacterial metabolites in sputum of cystic fibrosis patients were predictive for the increase in airway NO after antibiotic therapy in our small cohort.

*P. aeruginosa* is an opportunistic pathogen that frequently leads to chronic cystic fibrosis airways infections. Extending previous studies on SCFA-mediated growth inhibition of *Pseudomonas* species *in vitro* [37], we compared the effects of low and high millimolar concentrations of SCFAs and the pH-dependent nature of their effect on *P. aeruginosa* growth. We found that while high millimolar concentrations impaired growth, in line with earlier reports [37, 38], low millimolar concentrations provided a transient boost in growth during the mid-log phase. *P. aeruginosa* growth was universally reduced with decreasing pH in the presence of SCFAs. Furthermore, we confirmed these SCFA effects in microaerobic conditions. It is also conceivable that SCFAs may influence *P. aeruginosa* biofilm formation, but this was not investigated in these studies. Together, our results therefore show that SCFAs act both on the host to aggravate inflammatory responses and on colonising bacteria to increase their growth. These findings may also be of relevance in other anaerobic pulmonary infections such as empyema or lung abscess, where SCFAs are also detectable and correlate with positive anaerobic bacterial cultures [39].

Lately, there has been a surge of interest in SCFAs with the publication of several reports about SCFAs and their role in maintaining colonic regulatory T (Treg) cells [8, 40]. These studies showed that germ-free mice, deficient in SCFAs, are also deficient in Tregs and that faecal extracts from germ-free or antibiotic-treated mice poorly induce Foxp3+ Tregs *in vitro*. Butyrate was identified as particularly important for generating Tregs and this effect was *Fjap2*-dependent [8]. The balance between T-helper (Th)17 cells and Tregs is closely linked to inflammation and tolerance in the intestine [41]. As the Th17 pathway primarily evokes a neutrophil response, this is particularly interesting in the context of the prevalent neutrophilia found in cystic fibrosis lung disease [18, 42]. Given the similarities of the mucosal environments of the gut and the lungs, it will be important to investigate whether SCFAs can modulate the Th17/Treg axis in the cystic fibrosis airways [43]. The cell type-specific expression patterns of FFAR2 and other SCFA receptors in the airways are still unclear, but their elucidation may provide insight into the mechanism of SCFA activity and target cell populations.

In summary, our data suggest that SCFAs in concentrations found in sputum from cystic fibrosis patients exert cystic fibrosis-specific effects on airway epithelium inflammatory responses, induction of iNOS and *P. aeruginosa* growth. Further studies are needed to better characterise the role of these molecules in cystic fibrosis airway inflammation and to understand whether SCFAs in cystic fibrosis sputum can be used as markers of anaerobic bacterial activity or predictors of response to antimicrobial therapy.

**Acknowledgements**

We thank Kervan Rivera-Rufner (Dept of Nutritional Sciences, University of Toronto, Toronto, ON, Canada), Darakhshanda Shenhaz and Haiful Huang (Research Institute, The Hospital for Sick Children, Toronto, ON) for excellent technical assistance. We thank David N. Douda (Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA), Helena Obernolte, Armin Braun and Katharina Sewald (Fraunhofer ITEM, Hannover, Germany) for helpful discussions. We thank Christine Bear (Research Institute, The Hospital for Sick Children) for providing cystic fibrosis epithelial cell lines and Neil B. Sweeney (The Hospital for Sick Children) for providing a clinical isolate of *Pseudomonas aeruginosa*. Primary human bronchial epithelial cells and cell culture media were provided by the Primary Airway Cell Biobank from the Cystic Fibrosis Translational Research Centre at McGill University (Montreal, QC, Canada), supported by Cystic Fibrosis Canada. We acknowledge Hailey Craig-Barnes at the Analytical Facility for Bioactive Molecules of the Centre for the Study of Complex Childhood Diseases (CSCCD) at the Hospital for Sick Children (Toronto, ON, Canada), for multiplex ELISA services. The CSCCD was supported by the Canadian Foundation for Innovation (Ottawa, ON, Canada). Portions of this manuscript were published as part of the Master’s thesis of Peyman Ghorbani and as an abstract at the European Respiratory Society’s annual meeting in 2012 (Vienna, Austria).

**References**


Litman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845–858.
